THE MYOCARDIUM OF FETUSES WITH ENDOCARDIAL FIBROELASTOSIS CONTAINS A PAUCITY OF B AND T CELLS COMPARED WITH NORMAL CONTROLS  by Fernandes, Nisha
A44.E422
JACC March 9, 2010
Volume 55, issue 10A
  CONGENITAL CARDIOLOGY SOLUTIONS
 (PEDIATRIC CARDIOLOGY AND ADULT CONGENITAL HEART DISEASE)
THE MYOCARDIUM OF FETUSES WITH ENDOCARDIAL FIBROELASTOSIS CONTAINS A PAUCITY OF B AND 
T CELLS COMPARED WITH NORMAL CONTROLS
ACC Poster Contributions
Georgia World Congress Center, Hall B5
Monday, March 15, 2010, 3:30 p.m.-4:30 p.m.
Session Title: Fetal and Neonatal Cardiology
Abstract Category: Pediatric Cardiology
Presentation Number: 1228-397
Authors: Nisha Fernandes, The Hospital for Sick Children, Toronto, ON, Canada
Background: Endocardial fibroelastosis (EFE) and dilated cardiomyopathy (DCM) in fetuses born to mothers with anti-Ro/La antibodies have 
been found to contain myocardial B and T lymphocytes. We hypothesize that fetuses with EFE + idiopathic DCM without antibodies may also exhibit 
increased immune cellular activity.
Methods: Fetuses were identified from the pathology database. Paraffin tissue sections of the right and left ventricle and interventricular septum 
were stained for T cell (CD3, CD4, CD7, CD8), B cell markers (CD19, CD20, CD79.a) and CD45 (all cell lineages) and analyzed digitally.
Results: N=14 fetuses between 19 - 41 weeks gestation were included. None of the mothers had autoimmune disease or anti Ro/La antibodies. 
N=5 had EFE + DCM, 4 had EFE + structural heart disease (hypoplastic left heart 2, aortic stenosis 1, dysplastic tricuspid and pulmonary valves 1), 
and 5 normal controls (pregnancy termination 2, birth asphyxia 2, motor vehicle accident 1). A total of 203 sections were analyzed. Normal controls 
had demonstrable B and T cell populations diffusely within the myocardium. The EFE + DCM group had less B cells than the control group (2.0 vs. 
6.0 cells/section, p=0.005, specifically CD79a: 3.0 vs. 8.0 cells/section, p=0.004)). The EFE + heart disease group had less B cells (2.5 vs. 6.0 
cells/section, p=0.08, specifically CD20: 1.0 vs. 4.0 cells/section, p=0.002) and less T cells (4.0 vs. 7.0 cells/section, p=0.04, specifically CD3: 
4.0 vs. 12.5 cells/section, p<0.001) than the control group. Both the EFE + DCM group and the EFE + heart disease group had fewer CD45 cells 
compared to controls (31.0 vs. 73.5 cells/section, p=0.002 for the EFE + DCM group and 40.0 vs. 73.5 cells/section, p=0.007 for the EFE + heart 
disease group).
Conclusion: The myocardium of fetuses with EFE + DCM or structural heart disease contain smaller numbers of B and T lymphocytes compared 
with normal controls, suggesting a different pathophysiology from antibody-mediated disease. This suggests that targeted anti-inflammatory 
therapies in the 2nd and 3rd trimester may not improve outcome.
